Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Discoid Lupus Erythematosus
Interventions
DRUG

CC-10004

20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment

Trial Locations (1)

10016

New York University Tisch Hospital, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

NYU Langone Health

OTHER